Sanofi-aventis announced a research collaboration with Harvard University. The goal of the collaboration is to advance knowledge in the area of human health through basic and applied research and to promote scientificex change between Harvard University and sanofi-aventis. The focus of this collaboration is translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation. Steven E. Hyman MD, Provost of Harvard University said, “I’m delighted by the collaboration with sanofi-aventis, which joins together leaders in academic research and industry to more rapidly advance groundbreaking research from the lab to the clinic. This collaboration exemplifies Harvard’s commitment to creatively partner with industry in ways that we hope will push the boundaries of translational science, and advance our mandate of serving the public interest by making the fruits of our research available to society.
The collaboration will support a number of activities over the term of the agreement through the granting of funding awards. Harvard University investigators will propose research projects across a wide range of areas. The funded projects will be selected by a Joint Scientific Steering Committee comprised of representatives of sanofi-aventis and Harvard, respectively.
Friday, Feb 27th
Last update:12:00:00 AM GMT
Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafeni...